Stay updated with breaking news from Key Program Achievements. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PreHevbrio global net revenue increased 52% quarter-over-quarter from Q2 to Q3 2023 Continued execution across earlier-stage pipeline, including: Initiation of Phase 2b study of VBI-1901 in...
PreHevbrio global net revenue increased 48% quarter-over-quarter from Q1 to Q2 2023 - redefined, highly targeted commercial field team deployed at the end of Q2 Expanded hepatitis B... -Today at 08:04 am- MarketScreener
PreHevbrio global net revenue increased 90% quarter-over-quarter from Q4 2022 to Q1 2023 as access to PreHevbrio continues to broaden – now available at several U.S. retail pharmacy chains... | May 15, 2023
(2022-05-09 | NDAQ:VBIV) VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update